Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration

Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancer VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) a biopha

By: financialpost.com

Sep 17 2024
0
0 Views

Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancer Read More

CI Financial Reports Total Assets of $509.2 Billion for August 2024

EnviroGold Global Announces Appointment of Chief Operating Officer

JBS Teams With US Firm to Turn Cow, Chicken Waste Into Energy

Prime Drink Group Announces Results of Its Annual General and Special Meeting of Shareholders

Draganfly and Nightingale Security Selected by Fortune 25 Oil and Gas Company to Develop Autonomous Drone-in-a-Box Remote Sensing Solution

Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration

Brixton Metals Provides Initial Assay Results from its Maiden Drill Program at the Cirque Cu-Mo Porphyry Target

Major companies abandon an LGBTQ+ rights report card after facing anti-diversity backlash

French Power Turns Negative as Demand Undershoots Estimates

ApplyBoard secures a $100 million CAD financing deal with RBCx

Rally in Emerging-Market Assets Spreads Ahead of Fed Meeting

Compass Minerals Reports Preliminary Fiscal 2024 Third-Quarter Results

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration

Related